Efficacy and Safety of Ryanodex® (EGL-4104) as Adjuvant Treatment in Subjects With Exertional Heat Stroke (EHS)
Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
Study EGL-4104-C-1502 is a phase 2, single-site, open-label, randomized, 2-arm parallel study
of Ryanodex for the adjuvant treatment of exertional heat stroke (EHS) administered
intravenously (IV), to current standard of care (SOC). SOC for the treatment of EHS is
defined as effective body cooling, which should be implemented as quickly as available after
diagnosis of exertional heat stroke.